Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT05261646 Withdrawn - Clinical trials for Chemotherapy-Induced Thrombocytopenia

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Start date: April 15, 2022
Phase: Phase 3
Study type: Interventional

The study is aimed to evaluate the efficacy of different doses of hetrombopag compared to placebo, measured by the proportion of subjects that can complete two planned consecutive chemotherapy cycles with no modification of chemotherapy regimen (i.e., delayed start, dose reduction, omission, or discontinuation) because of thrombocytopenia [platelet count <100×109/L], to determine an optimal dose of hetrombopag and to demonstrate its superiority over placebo.

NCT ID: NCT05259553 Recruiting - Chemotherapy Clinical Trials

Biomarkers in Multiple Myeloma

VESICOM
Start date: May 20, 2022
Phase: N/A
Study type: Interventional

The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.

NCT ID: NCT05251727 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Start date: March 24, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

NCT ID: NCT05251337 Completed - Anxiety Clinical Trials

Use of Aromatherapy to Reduce Symptom Burden

Start date: March 7, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of inhaled aromatherapy on symptoms of nausea/vomiting and anxiety in patients who have received a stem cell transplant. Aromatherapy involves essential oils from aromatic plants that can be absorbed into the body in different ways. Our study will be using inhaled aromatherapy, which has been found helpful for symptoms such as nausea/vomiting and anxiety.

NCT ID: NCT05246670 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Start date: May 16, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.

NCT ID: NCT05244837 Recruiting - Safety Clinical Trials

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Start date: December 22, 2020
Phase: Phase 2
Study type: Interventional

To explore the related biomarkers for safety and efficacy of the combination of chemotherapy and tislelizumab in non-small cell lung cancer

NCT ID: NCT05242874 Completed - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Fosaprepitant , Tropisetron and Olanzapine for the Prevention of Nausea and Vomiting in Patients With Breast Cancer

Start date: January 1, 2022
Phase: Phase 3
Study type: Interventional

Standard antiemetic therapy without dexamethasone for the prevention of nausea and vomiting in patients with breast cancer

NCT ID: NCT05239663 Recruiting - Breast Cancer Clinical Trials

GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer

Start date: February 8, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the prophylactic effects of Ganglioside-Monosialic Acid in post-chemotherapy cognitive impairment in patients with early operable breast cancer.

NCT ID: NCT05236582 Recruiting - Clinical trials for Chemotherapy-induced Thrombocytopenia

Herombopag for Chemotherapy-induced Thrombocytopenia

Start date: March 14, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors

NCT ID: NCT05230771 Not yet recruiting - Surgery Clinical Trials

Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

Start date: April 1, 2022
Phase: Phase 3
Study type: Interventional

This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.